Bayer/Regeneron Will Initiate VEGF Trap-Eye Phase III Trial In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
Further development follows the release of a positive Phase II interim analysis of the wet age-related macular degeneration candidate.
You may also be interested in...
Merck Obtains Access To SurModics’ Ophthalmic Drug Delivery System In Potential $300 Million Deal
I-vation system is currently being studied in combination with triamcinolone acetonide for treatment of diabetic macular edema.
Merck Obtains Access To SurModics’ Ophthalmic Drug Delivery System In Potential $300 Million Deal
I-vation system is currently being studied in combination with triamcinolone acetonide for treatment of diabetic macular edema.
ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin
Bayer receives ex-U.S. rights to develop and market the recombinant thrombin therapy.